NCCN 2018 Nursing Forum: Oncology Nursing in Hematologic Malignancies
The management of cancer is constantly evolving through the introduction of new developments related to cancer treatment and supportive care. This has created gaps in the ability of hematology/oncology nurses to stay up-to-date with comprehensive and clinically relevant information on current and critical issues affecting the management of hematologic malignancies that can help to optimize patient education and care.
As the management of patients with hematologic malignancies has become more complex, the need for practical, clinically relevant information that can be implemented in the practice setting to optimize patient education and care for patients with hematologic malignancies has become increasingly necessary.
This educational program is designed to meet the educational needs of oncology nurses who manage patients with hematologic malignancies.
Following this program, participants should be able to:
- Evaluate advances in the management of patients with hematologic malignancies and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
- Review issues related to toxicities and adverse events associated with therapy with CAR T cells, immune checkpoint inhibitors, and hematopoietic cell transplantation and implement appropriate strategies for managing these in the healthcare setting.
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN Continuing Education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses no relevant financial relationships:
Ruth-Ann Gordon, MSN, FNP-BC, OCN
Diane Hill-Polerecky, RN, MSN, BMTCN
Chrstina Kiss, MSN, OCN, ANP-BC
The faculty listed below discloses the following relevant financial relationships:
Lauren Spendley, MSN, AGNP-BC
Celgene Corporation: Scientific Advisor
Juno Therapeutics: Scientific Advisor
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (Employed by NCCN until August 10, 2018); Joan S. McClure, MS (Employed by NCCN until August 1, 2018); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Gary J. Weyhmuller, MBA, SPHR
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jennifer L. Burns, BS; Mary A. Dwyer, MS, CGC; Alyse Johnson-Chilla; Ndiya Ogba, PhD; Lenora Pluchino, PhD; Jillian Scavone, PhD; Hema Sundar, PhD
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
NCCN designates this educational activity for a maximum of 2.6 contact hours.
- 2.60 ANCC contact hours
- 2.60 Participation